Online survey on clinical care, health problems and psychosocial stress during the corona pandemic in children and adolescents with chronic inflammatory bowel disease (IBD) (COVID19-CED-PÄD)

• Conditions: K50; K51; K52; U07.1; Crohn disease [regional enteritis]; Ulcerative colitis; Other noninfective gastroenteritis and colitis; COVID-19, virus identified

• Registration Number: DRKS00022500
• Lead Sponsor: Klinikum der Universität München (LMU Klinikum)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-08-21
• Study Completion: 2021-03-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

Patients (male, female, divers) with diagnosed IBD (Crohn's disease, ulcerative colitis, unclassified IBD) with or without comorbidity, with or without therapy at the time of inclusion, age = 20 years and living in Germany.

Exclusion Criteria

When inclusion criteria cannot be met.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The online survey has been taken place in 2020 from August 25 to December 10.<br><br>The following questions should be answered by conducting this survey-based study: <br>1) How did the pandemic and the lock-down impact medical care? <br>a) on planned but postponed or cancelled outpatient or inpatient visits or surgery appointments, <br>b) to the IBD associated medication (reduction, reorientation) by the physicians (general practitioners, at IBD outpatient clinic) or patients/parents (without consulting a physician) so far? <br>c) How many patients have postponed a planned outpatient visit for infusion of biologicals due to symptoms / COVID-19 contact / return home from high-risk areas / occupational exposure as indicated in the telephone/ e-mail consultation? <br>d) Did any IBD flare occur during a pandemic-related change in care/ medication?

Secondary Outcome Measures

Name	Time	Method
2) How have patients experienced tele-medicine practiced in the clinic setting so far? Did they consider that they received sufficient information and care? <br>3) How did the pandemic influence social factors and mental health of the IBD patients regarding medication and severity of the disease? Are there any variations compared to the KoCo-19 cohort?